▶주메뉴 바로가기
▶본문 바로가기
Bio company SillaJen announced Oct. 31 it will pay back 110 billion won (94.25 million), which it received by issuing convertible bonds, to Kiwoon Securities in March. “The annual interest rate for convertible bonds that were issued, including the ones issued to Kiwoon, rose from 3 to 6 percent a...
South Korea’s Health Ministry said Oct. 30 that it is considering revoking Kolon Life Science’s innovative drug company certification for mislabeling and falsely reporting ingredients in its gene therapy drug, Invossa. A key material used in Invossa came from a kidney cell instead of from car...
Sales of biosimilar Remsima by South Korean bio-pharmaceutical firm Celltrion reached $77 million in the United States during the third quarter of this year, industry data showed Oct. 30. Sales of the biosimilar drug to treat autoimmune diseases jumped 8 percent on-year during the July-Septembe...
The 30th CPhI Worldwide 2019, the biggest global event of the year for the pharmaceutical industry, is set to take place at Messe Frankfurt in Germany from Nov. 5 to 7. Every year, CPhI brings together more than 100,000 pharmaceutical professionals to network for business opportunities at venues a...
South Korean biotech firm Bridge Biotherapeutics announced Oct. 25 that it had received preliminary screening approval for Kosdaq listing. The company applied for approval Sept. 3 and expects to be listed on the second-tier Kosdaq market in December this year. “We will continue to develop and ad...
The Ministry of Food and Drug Safety on Oct. 16 ordered Medytox to withdraw and dispose of the entire batch of its botulinum toxin Meditoxin produced for exports. The problematic products were produced on Oct 6, 10 and 19 of 2016 and its expiry date is Oct 5, 11 and 18 this year, respectively. The...
Daewoong Pharmaceutical announced Oct. 16 it has launched its botulinum toxin under the name Nuceiva in Canada. It is the first South Korean company to enter the Canadian market with a botulinum toxin brand. “Like the US market, Canada also has only three types of botulinum toxins which have bee...
South Korea’s Supreme Court announced on Oct. 16 that it has approved a request by Samsung BioLogics to suspend the execution of penalties by the financial watchdog on Oct. 11. The court’s recent decision came after the lower courts approved the same request of Samsung BioLogics in February an...
Daewoong Pharmaceutical on Oct. 7 denied allegations by Medytox that it stole manufacturing secrets, including its Hall A Hyper strain, to develop its botulinum toxin Nabota. “Medytox is saying that its Hall A Hyper strain, which was proven to not form spores by multiple professionals for decades...
South Korean drugmaker Daewoong Pharmaceutical said Oct, 2 it has won approval from European authorities for the sale of its botulinum toxin product. The European Commission accepted Daewoong’s application to sell Nabota, Korea’s first botulinum toxin product to receive the green light for th...
Samsung BioLogics has won a lawsuit against Switzerland-based Lonza to nullify its patents involving its cell line development technology in South Korea, according to sources Oct. 1. The court noted Lonza’s patented technology is not new compared to the one that is being widely used and it is als...
South Korean biotech firm Genexine announced on Sept. 27 that it has signed a contract with the Thai company KinGen Holdings to establish a 50:50 joint venture named KinGen Biotech. KinGen Holdings is a Thai consortium that is backed by the government, schools and divers investors, according to Ge...
Celltrion Healthcare on Sept. 27 announced its decision to expand sales in the Middle East. He company has got approval to exclusively supply Remsima, its version of Johnson & Johnson’s Remicade from the third quarter this year. According to the company, its successful bid was due to its aggress...
Celltrion Group on Sept. 20 announced that European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended giving sales approval for Remsima SC. CHMP is responsible for preparing the opinions to EMA on questions concerning human medicines based on scientific evidence. ...
Medytox has participated in the seed-funding round of US startup LifeSprout, according to industry sources on Sept. 16. Although the Korean company declined to confirm the specific amount that it has funded, a local news outlet reported that it invested around $1.5 million in this round. The US c...
Korean builders nervous about possible setbacks in Middle East
HD Hyundai chair receives honorary doctorate from HUFS
SC Bank Korea offers special interest rate for new members
Hyundai-Kia marks 40 years of partnerships with over 100 suppliers: report
Samsung expected to introduce new Exynos processor in next Galaxy series
Woori, KB ink QR code payment partnership with Cambodia